Clinical Trials | November 15, 2023
Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Phase 3 data expected in the second half of 2024
Phase 3 data expected in the second half of 2024
Narayana Hrudayalaya has reported total income of Rs. 1323.64 crores during the period ended September 30, 2023
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Subscribe To Our Newsletter & Stay Updated
